Kevin Hrusovsky is the chairman, president and CEO of Quanterix, a precision health biotechnology company.
Hrusovsky joined the company in 2014 as executive chairman of the board. In 2015, he became president and CEO, working to digitize biomarker analysis to advance the science behind precision health. In 2017, he took Quanterix public in what became one of the most successful IPOs for a life sciences company in recent history. Under his tenure, the company also acquired Aushon and regained the rights to its Simoa technology.
In addition to his role at Quanterix, Hrusovsky also serves as the founder and chairman of Powering Precision Health, the annual summit that has become the industry’s leading platform for advancing the deep science behind precision health.
Prior to his work with Quanterix and Powering Precision Health, Hrusovsky served as the president of life sciences and technology for PerkinElmer from 2011 to 2013. Previously, for more than eight years, he was the president and CEO of Caliper Life Sciences, now part of PerkinElmer. He also worked with Zymark Limited as the company’s president and CEO from 1996 to 2003, with FMC for four years as president of pharmaceuticals and head of international agricultural products, and he held various high-level management positions for Dupont starting in 1983.
Hrusovsky has earned numerous awards and accolades for his leadership and achievements in the healthcare industry, including being a three-time finalist for Ernst & Young’s Entrepreneur of the Year award, receiving the Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award, both from Ohio State University, and receiving the BBJ Innovation All-Star Award.
He currently serves as a board member for Solect Energy Development LLC, 908 Devices, Brown University Biomedical, Massachusetts Biotech Coucil Curriculum, Boston Children’s Hospital Strategy and the Association for Lab Automation. He holds an honorary doctorate from Framingham State University and helped build curriculum for the Institute for Strategy and Competitiveness at Harvard Business School.
Hrusovsky earned both his bachelor’s degree in mechanical engineering and his M.B.A. from Ohio State University.
What is E Kevin Hrusovsky's net worth?
The estimated net worth of E Kevin Hrusovsky is at least $10.70 million as of July 5th, 2022. Mr. Hrusovsky owns 910,249 shares of Quanterix stock worth more than $10,695,426 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Hrusovsky may own. Learn More about E Kevin Hrusovsky's net worth.
How do I contact E Kevin Hrusovsky?
Has E Kevin Hrusovsky been buying or selling shares of Quanterix?
E Kevin Hrusovsky has not been actively trading shares of Quanterix during the last quarter. Most recently, E Kevin Hrusovsky sold 960 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $16.57, for a transaction totalling $15,907.20. Following the completion of the sale, the chairman now directly owns 910,249 shares of the company's stock, valued at $15,082,825.93. Learn More on E Kevin Hrusovsky's trading history.
Who are Quanterix's active insiders?
Are insiders buying or selling shares of Quanterix?
During the last year, Quanterix insiders bought shares 1 times. They purchased a total of 47,000 shares worth more than $624,630.00. During the last year, insiders at the sold shares 2 times. They sold a total of 2,500 shares worth more than $60,025.00. The most recent insider tranaction occured on August, 20th when Director David R Walt bought 47,000 shares worth more than $624,630.00. Insiders at Quanterix own 6.9% of the company.
Learn More about insider trades at Quanterix. Information on this page was last updated on 8/20/2024.
